Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
Holding RAPT?
Track your performance easily
RAPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.73 - $27.35
Previous Close$1.96
Volume260.10K
Average Volume (3M)303.37K
Market Cap
$68.41M
Enterprise Value-$40.70M
Total Cash (Recent Filing)$114.84M
Total Debt (Recent Filing)$5.73M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 07, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.12
Shares Outstanding34,903,476
10 Day Avg. Volume249,480
30 Day Avg. Volume303,370
Standard Deviation0.31
R-Squared0.00326
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.52
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$7.50Price Target Upside282.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
RAPT Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe net loss per share was slightly better than the consensus estimate, indicating a small positive variance.
LiquidityRAPT ended 2Q24 with ~$114.8M in cash and equivalents, which ought to provide an operational runway extending through mid-2025.
Regulatory DiscussionsManagement believes there is sufficient data, even if not statistically significant, to inform the path forward and support regulatory discussions on future development.
Bears Say
Clinical SetbacksRisks include negative proof-of-concept efficacy data for zelnecirnon in Phase 2b testing in AD, failure to advance zelnecirnon into pivotal testing in allergic conditions, and inability to secure regulatory approval for zelnecirnon.
Financial StrainThe company announced a 40% workforce reduction to conserve cash resources, indicating financial strain.
Regulatory IssuesThe FDA placed a clinical hold on zelnecirnon trials due to a case of liver failure, leading to the closure of Phase 2 trials.
---
Ownership Overview
188.85% Insiders
2355.21% Mutual Funds
2896.34% Other Institutional Investors
3490.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $1.73 and its highest was $27.35 in the past 12 months.
What is RAPT Therapeutics’s market cap?
Currently, no data Available
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 35 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.72 by $0.01.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -$0.56.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 34,903,477 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.72. Following the earnings report the stock price went down -2.075%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Among the largest hedge funds holding RAPT Therapeutics’s share is Ardsley Advisory Partners. It holds RAPT Therapeutics’s shares valued at 2M.
---
RAPT Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (282.65% Upside)
$7.50 (282.65% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.47%
12-Months-Change
Fundamentals
Return on Equity
-77.97%
Trailing 12-Months
Asset Growth
-42.39%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
RAPT Stock 12 Month Forecast
Average Price Target
$7.50
▲(282.65% Upside)
Technical Analysis
Best Analysts Covering RAPT
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-42.31%
assigned a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -42.31% per trade.
---